TY - JOUR
T1 - Vascular stenosis in a child with visual pathway glioma treated with bevacizumab
T2 - a case report and review of literature
AU - Pilotto, Chiara
AU - Beshlawi, Ismail
AU - Thomas, Adam
AU - Grundy, Richard G.
N1 - Publisher Copyright:
© 2017, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Background: Bevacizumab (BVZ) is a vascular endothelial growth factor inhibitor that has been widely accepted since its introduction into the cancer pharmacopoeia. Anecdotal reports suggested improvements in vision in children with visual pathway glioma. Case presentation: We report a boy with visual pathway glioma whose vision had deteriorated significantly on vincristine and carboplatin, to the point that he was registered blind. Following bevacizumab therapy, there was a dramatic improvement in vision with reduction in tumour volume. However, following 20 doses of BVZ given over 19 months, he developed a significant cerebrovascular stenosis. Conclusion: The BVZ-induced cerebrovascular diseases in children are extremely rare but potentially serious. Importantly, stenosis has not been previously described in literature.
AB - Background: Bevacizumab (BVZ) is a vascular endothelial growth factor inhibitor that has been widely accepted since its introduction into the cancer pharmacopoeia. Anecdotal reports suggested improvements in vision in children with visual pathway glioma. Case presentation: We report a boy with visual pathway glioma whose vision had deteriorated significantly on vincristine and carboplatin, to the point that he was registered blind. Following bevacizumab therapy, there was a dramatic improvement in vision with reduction in tumour volume. However, following 20 doses of BVZ given over 19 months, he developed a significant cerebrovascular stenosis. Conclusion: The BVZ-induced cerebrovascular diseases in children are extremely rare but potentially serious. Importantly, stenosis has not been previously described in literature.
KW - Adverse effects
KW - Bevacizumab
KW - Cerebrovascular stenosis
KW - Visual pathway glioma
UR - http://www.scopus.com/inward/record.url?scp=85038086068&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038086068&partnerID=8YFLogxK
U2 - 10.1007/s00381-017-3676-7
DO - 10.1007/s00381-017-3676-7
M3 - Article
C2 - 29249070
AN - SCOPUS:85038086068
SN - 0256-7040
VL - 34
SP - 781
EP - 785
JO - Child's Nervous System
JF - Child's Nervous System
IS - 4
ER -
